[go: up one dir, main page]

Jones et al., 2008 - Google Patents

From natural products to small molecule ketone histone deacetylase inhibitors: development of new class specific agents

Jones et al., 2008

Document ID
8378783813197963013
Author
Jones P
Steinkuhler C
Publication year
Publication venue
Current pharmaceutical design

External Links

Snippet

Histone deacetylases (HDACs) are one of two counteracting enzyme families whose activity controls the acetylation state of lysine protein residues, notably those contained in the N- terminal extensions of the core histones. Deregulation of the acetylation state of specific …
Continue reading at www.ingentaconnect.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links

Similar Documents

Publication Publication Date Title
Jones et al. From natural products to small molecule ketone histone deacetylase inhibitors: development of new class specific agents
CN1646558B (en) Histone deacetylase inhibitors
Komatsu et al. Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity
Furumai et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases
Ma et al. Selective histone deacetylase inhibitors with anticancer activity
Bieliauskas et al. Isoform-selective histone deacetylase inhibitors
Kim et al. Histone deacetylase in carcinogenesis and its inhibitors as anti-cancer agents
Pojani et al. Romidepsin (FK228), A histone deacetylase inhibitor and its analogues in cancer chemotherapy
Nakao et al. Azumamides A–E: histone deacetylase inhibitory cyclic tetrapeptides from the marine sponge Mycale izuensis
Jung Inhibitors of histone deacetylase as new anticancer agents
Jones et al. A series of novel, potent, and selective histone deacetylase inhibitors
Vigushin et al. Targeted histone deacetylase inhibition for cancer therapy
Rodriquez et al. Chemistry and biology of chromatin remodeling agents: state of art and future perspectives of HDAC inhibitors
Newkirk et al. Discovery, biological activity, synthesis and potential therapeutic utility of naturally occurring histone deacetylase inhibitors
Marson Histone deacetylase inhibitors: design, structure-activity relationships and therapeutic implications for cancer
Maolanon et al. Natural and synthetic macrocyclic inhibitors of the histone deacetylase enzymes
Monneret Histone deacetylase inhibitors for epigenetic therapy of cancer
Song et al. Proteases and their modulators in cancer therapy: challenges and opportunities
Li et al. Histone deacetylase inhibitors: an attractive strategy for cancer therapy
Elaut et al. The pharmaceutical potential of histone deacetylase inhibitors
Servatius et al. Total synthesis of Trapoxin A, a fungal HDAC inhibitor from Helicoma ambiens
Cheng et al. Progress in the discovery of macrocyclic histone deacetylase inhibitors for the treatment of cancer
Ganesan Targeting the zinc-dependent histone deacetylases (HDACs) for drug discovery
EP1640380B1 (en) Histone deacetylase inhibitor and process for producing the same
Kollar et al. Selective inhibitors of zinc-dependent histone deacetylases. Therapeutic targets relevant to cancer